DENTSPLY SIRONA Inc (NASDAQ:XRAY) has received a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $54.57.
XRAY has been the subject of a number of research analyst reports. Wellington Shields raised shares of DENTSPLY SIRONA from a “hold” rating to a “gradually accumulate” rating in a research report on Friday, August 2nd. Wolfe Research began coverage on shares of DENTSPLY SIRONA in a research report on Thursday, May 30th. They set a “peer perform” rating for the company. Evercore ISI began coverage on shares of DENTSPLY SIRONA in a research report on Friday, July 26th. They set an “in-line” rating for the company. Guggenheim began coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 17th. They set a “neutral” rating and a $54.00 price objective for the company. Finally, HC Wainwright reissued a “neutral” rating and set a $57.00 price objective (up previously from $55.00) on shares of DENTSPLY SIRONA in a research report on Tuesday, July 9th.
In related news, SVP Markus Boehringer sold 22,900 shares of DENTSPLY SIRONA stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $54.80, for a total transaction of $1,254,920.00. Following the transaction, the senior vice president now owns 49,849 shares in the company, valued at approximately $2,731,725.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Maureen J. Macinnis sold 15,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, June 10th. The shares were sold at an average price of $56.06, for a total transaction of $840,900.00. Following the transaction, the senior vice president now owns 25,360 shares in the company, valued at approximately $1,421,681.60. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 22,720 shares of company stock worth $1,223,243. 0.62% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Hanseatic Management Services Inc. bought a new position in DENTSPLY SIRONA during the 1st quarter valued at about $30,000. Altshuler Shaham Ltd lifted its position in shares of DENTSPLY SIRONA by 209.8% in the 2nd quarter. Altshuler Shaham Ltd now owns 505 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 342 shares during the period. Cornerstone Advisors Inc. lifted its position in shares of DENTSPLY SIRONA by 62.0% in the 2nd quarter. Cornerstone Advisors Inc. now owns 904 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 346 shares during the period. Van ECK Associates Corp purchased a new stake in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $54,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $58,000. Institutional investors and hedge funds own 97.06% of the company’s stock.
NASDAQ:XRAY traded up $1.09 during trading hours on Thursday, reaching $53.37. The company had a trading volume of 1,573,179 shares, compared to its average volume of 1,786,393. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.39 and a current ratio of 2.08. DENTSPLY SIRONA has a 52 week low of $33.93 and a 52 week high of $59.40. The stock has a market cap of $11.96 billion, a price-to-earnings ratio of 26.55, a price-to-earnings-growth ratio of 1.91 and a beta of 0.97. The company’s 50 day simple moving average is $55.89.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Friday, August 2nd. The medical instruments supplier reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. DENTSPLY SIRONA had a net margin of 2.67% and a return on equity of 9.19%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The firm’s revenue was down 3.1% on a year-over-year basis. On average, equities research analysts predict that DENTSPLY SIRONA will post 2.39 earnings per share for the current year.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Featured Story: Dead Cat Bounce
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.